Article Details

SLS009 Earns FDA Fast Track Designation for R/R PTCL - Targeted Oncology

Retrieved on: 2023-10-30 14:06:11

Tags for this article:

Click the tags to see associated articles and topics

SLS009 Earns FDA Fast Track Designation for R/R PTCL - Targeted Oncology. View article details on hiswai:

Excerpt

Where Monoclonal Antibodies and CAR T-cell Therapy Fit in R/R DLBCL. October 25th 2023 · FDA Approves Ivosidenib for IDH1-Mutated MDS. October 24th ...

Article found on: www.targetedonc.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo